Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Observational studies have given conflicting results about the effect of statins in preventing dementia and cognitive decline.
-
Current literature is conflicting with regard to the effects of statins on memory loss.
-
It has been suggested that patients undergoing treatment with recombinant interleukin-2 (rIL-2) may develop cognitive impairment.
-
Overall, 156 (12.5%) women reported taking oestrogen after onset of menopause.
-
We treated 17 patients who had moderate to severe Alzheimer's disease with oral tetrahydroaminoacridine (THA), a centrally active anticholinesterase, in a three-phase study.
-
The mean age was 74.2 ± 7.9 years, and 89 (74%) were female.
-
The mean age was 66 years (65.53 ± 9.31), and 51 (67.1%) participants being female.
-
Huntington's Disease (HD) is a severely debilitating neurodegenerative disorder in which sufferers exhibit different combinations of movement disorders, dementia, and behavioral or psychiatric abnormalities.
-
Quality pharmacological treatment can improve survival in many types of cancer.
-
Aducanumab is a novel disease-modifying anti-amyloid-beta (Aβ) human monoclonal antibody specifically targeted to the pathophysiology of Alzheimer's disease (AD).
-
Reversal genes and the candidate compounds were identified by the leave-one-out cross-validation procedure.
-
We identified 1,994 records in five different databases; after exclusion of duplicates, title and abstract screening, and full-text retrieval, 122 studies were finally included.
-
Vascular dementia (VD) is a neurocognitive disorder whose precise definition is still up for debate.
-
Based on a structured search on the ClinicalTrials.gov and the EudraCT databases, we identified 13 clinical trials testing 11 different approved anticancer agents (five tyrosine kinase inhibitors, two retinoid X receptor agonists, two immunomodulatory agents, one histone deacetylase inhibitor, and one monoclonal antibody) in the AD continuum.
-
These findings describe solanezumab effects on efficacy/safety measures in a mild AD population.
-
155 (85%) patients completed the trial (78 [88%] in dimebon group, 77 [82%] in placebo group).
-
The TRAILBLAZER-ALZ 6 study (NCT05738486) evaluated the effect of different donanemab dosing regimens on amyloid-related imaging abnormalities with edema/sulcal effusions (ARIA-E).
-
The steady-state plasma PK results were closely aligned with the previous 2-week PK in the ALZ-801 phase 1b study in APOE4 carrier subjects with AD, as well as a phase 1 7-day PK study in heathy elderly volunteers.
-
Alzheimer's disease, a progressive neurodegenerative pathology, is characterized by the accumulation of Amyloid-β plaques in the brain.
-
Buse, MD PhDDiabetes Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina (J.B.B.), and the LEADER Publication Committee on behalf of the LEADER Trial Investigators*Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-1569 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Comorbidities and complications associated with type 2 diabetes mellitus (T2DM) increase with age, making treatment of elderly persons with this condition challenging.
-
Key Messages: Our results suggest that benzodiazepine use is significantly associated with dementia risk.
-
In this FTIH study the Fc-inactivated anti-Aβ mAb GSK933776 engaged its target in plasma and CSF without causing brain ARIA-E/H in patients with mild AD or MCI.
-
We found little evidence to support wide-ranging effects of statins on health outcomes beyond their established beneficial effect on vascular disease.
-
Adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for the treatment of psychosis, aggression, or agitation in patients with Alzheimer's disease.
-
Cognition averaged 0.8 MMSE (mini-mental state examination) points better (95% CI 0.5-1.2; p<0.0001) and functionality 1.0 BADLS points better (0.5-1.6; p<0.0001) with donepezil over the first 2 years.
From across this topic
10 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- AChE Inhibitors and NMDA Receptor Antagonists in Advanced Alzheimer's Disease
- Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype
- Bright light therapy
- Cholinesterase inhibitors and beyond
- P2‐003: Clinical Trial Design of Cread: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Study to Evaluate Crenezumab Treatment in Patients with Prodromal‐To‐Mild Alzheimer’s Disease
- GABA and its receptors' mechanisms in the treatment of insomnia
- A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease
- Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting
- Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis
- Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial